This composite flow cytometric panel illustrates the bone marrow of a newly diagnosed primary plasma cell leukemia patient demonstrating CD38 +, λ-a-restricted, CD20-plasma cells.

IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their ...

Abnormal plasma cells begin to grow very quickly ... A four-drug regimen may also include an anti-CD38 monoclonal antibody.

an allogeneic CAR T-cell therapy targeting CD38, has administered the first dose to a patient in an investigator-initiated trial (IIT). KJ-C2320 is developed based on CARsgen’s THANK-uCAR platform. An ...

Sanofi’s Sarclisa (isatuximab) has been approved by the Medicines and Healthcare product Regulatory Agency (MHRA) as part of a combination treatment for newly diagnosed multiple myeloma (MM).

That included a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody ... of cancer cells and serum fee light chain biomarkers that indicate a plasma cell cancer.